However, in FAERS, mAbs such as trastuzumab and pertuzumab, along with CDK4/6 inhibitors like palbociclib, ribociclib, and abemaciclib, the odds of ILD was lower than in the early post-dose period. This evidence concerns the gene CDK4 and interstitial lung disease.